Hybrigenics S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
4,977.00
5,265.00
1,163.00
1,492.00
-
100
Cost of Goods Sold (COGS) incl. D&A
7,805.00
3,527.00
953.00
58.00
146.00
8,800
Gross Income
2,828.00
1,738.00
210.00
1,434.00
146.00
8,700
SG&A Expense
-
5,929.00
6,023.00
6,505.00
9,132.00
-
EBIT
3,436.00
-
-
-
9,126.00
8,700
Unusual Expense
59.00
-
252.00
-
-
-
Non Operating Income/Expense
1,000.00
790.00
438.00
485.00
1,167.00
1,000
Interest Expense
2.00
45.00
23.00
11.00
4.00
-
Pretax Income
2,379.00
3,151.00
5,571.00
4,606.00
7,939.00
-
Income Tax
601.00
573.00
591.00
614.00
646.00
-
Consolidated Net Income
1,778.00
2,578.00
4,980.00
3,992.00
7,293.00
7,500
Net Income
1,788.00
2,578.00
5,015.00
3,997.00
7,293.00
7,500
Net Income After Extraordinaries
1,788.00
2,578.00
5,655.00
2,737.00
6,629.00
7,500
Net Income Available to Common
1,788.00
2,578.00
4,375.00
4,178.00
8,081.00
7,500
EPS (Basic)
0.08
0.10
0.12
0.15
0.20
0.16
Basic Shares Outstanding
23,416.70
26,719.80
35,344.00
36,931.70
40,483.60
-
EPS (Diluted)
0.08
0.10
0.12
0.14
0.20
-
Diluted Shares Outstanding
23,416.70
26,719.80
35,344.00
36,931.70
40,483.60
-
EBITDA
3,082.00
3,544.00
5,573.00
5,043.00
8,980.00
-
Other Operating Expense
608.00
275.00
-
52.00
152.00
-
Non-Operating Interest Income
-
20.00
79.00
43.00
24.00
-
Minority Interest Expense
10.00
-
35.00
5.00
-
-

About Hybrigenics

View Profile
Address
3-5, impasse Reille
Paris Ile-de-France 75014
France
Employees -
Website http://www.hybrigenics.com
Updated 07/08/2019
Hybrigenics SA operates as a biopharmaceutical company, which engages in the research and development of targets and therapies against proliferative diseases. It develops inecalcitol for the treatment of prostate cancer, chronic lymphocytic leukemia, and chronic myeloid leukemia. The company was founded on December 29, 1997 and is headquartered in Paris, France.